Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors

Area of Science:

• Oncology
• Pharmacology
• Computational Biology

Background:

• Imatinib is a first-line therapy for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
• Drug resistance, often due to ABL kinase domain mutations, leads to treatment relapse in a significant proportion of CML patients.
• The impact of less common ABL mutations and the distinct resistance profiles of next-generation inhibitors remain incompletely understood.

Purpose of the Study:

• To computationally predict the drug sensitivity of 234 point mutations in the ABL kinase domain.
• To evaluate the sensitivity profiles of ABL mutations against imatinib and five next-generation tyrosine kinase inhibitors (TKIs).
• To provide comprehensive resistance profiles for both single and compound ABL mutations.

Main Methods:

• Utilized a computational docking approach to predict drug sensitivity.
• Validated the computational model against published data for known frequent mutations.
• Analyzed 234 reported point mutations and several compound mutations in the ABL kinase domain.

Main Results:

• The computational approach showed good correlation with existing experimental and clinical data.
• Distinct drug sensitivity profiles were observed for various ABL mutants against different TKIs.
• Comprehensive sensitivity and resistance profiles were generated for a wide range of ABL mutations against multiple inhibitors.

Conclusions:

• Computational analysis is a valuable tool for predicting ABL mutation drug sensitivity in CML.
• The study provides crucial insights into resistance mechanisms against imatinib and newer TKIs.
• Findings can inform personalized treatment strategies for CML patients with diverse resistance mutations.